Cagrilintide
Novo Nordisk
Standalone amylin analogue, distinct from its CagriSema combination.
Selected study results
REDEFINE 1 · cagrilintide monotherapy armMean body-weight reductionBody weight decreased 11.8% · 68 weeks · Phase 3
Mean body-weight reduction · 68 weeks
Study focus: Weight management without type 2 diabetes
Adults without type 2 diabetes; parent trial N includes all four arms · Cagrilintide 2.4 mg once weekly vs placebo · Trial N=3417 · Adherence-based estimate; sponsor-reported subanalysis. Results & methods ↗
This is the monotherapy arm of the CagriSema parent trial, not a RENEW result. The estimate assumes treatment adherence; Phase 2 dose-finding results remain below.
Standalone dose-finding trialMean body-weight reductionBody weight decreased 10.8% · 26 weeks · Phase 2
Mean body-weight reduction · 26 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a weight-related complication, without diabetes · 4.5 mg once weekly vs placebo · Trial N=706 · Trial-product estimand. Results & methods ↗
This is standalone cagrilintide, not CagriSema. The trial also included liraglutide 3 mg, with 9.0% mean reduction.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: RENEW 1 Phase 3 monotherapy trial registered.
Next: RENEW efficacy and safety readouts.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies3 records
Cagrilintide / CagriSema · pediatric study
Pediatric weight managementShared protocol evaluating cagrilintide and CagriSema in children/adolescents; one protocol linked from both relevant profiles. Investigational pediatric use.
REDEFINE 1 · cagrilintide monotherapy arm
Weight management without type 2 diabetesMonotherapy arm within the four-arm parent trial; 2.4 mg cagrilintide versus placebo. Same registered study as the CagriSema profile, not a separate RENEW trial.
RENEW 1
Weight managementStandalone cagrilintide monotherapy study for chronic weight management.
Phase 2 studies1 record
Standalone cagrilintide dose-finding study
Weight managementPublished dose-ranging monotherapy study in adults with obesity or overweight and a weight-related complication, without diabetes. The cagrilintide arm within REDEFINE 1 is not a separate standalone trial.
